 Histogen Inc NASDAQ: HSTO and its partner Amerimmune LLC have announced additional findings from its Phase 1 study of emricasan in mild symptomatic COVID-19 patients. As previously reported, emricasan was shown to be safe and well-tolerated during the 14 days of dosing and at the day 45 follow-up, compared to placebo. 